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PDA detectorAbstract A simple, precise and accurate method was developed and validated for analysis of Ket-
orolac Tromethamine in eye drop formulation. An isocratic HPLC analysis was performed on
Kromosil C18 column (150 cm · 4.6 mm · 5 lm). The compound was separated with the mixture
of methanol and ammonium dihydrogen phosphate buffer in the ratio of 55:45 V/V, pH 3.0 was
adjusted with O-phosphoric acid as the mobile phase at ﬂow of 1.5 mL min1. UV detection was
performed at 314 nm using photo diode array detection. The retention time was found to be
6.01 min. The system suitability parameters such as theoretical plate count, tailing and percentage
RSD between six standard injections were within the limit. The method was validated according to
ICH guidelines. Calibrations were linear over the concentration range of 50–150 lg mL1 as indi-
cated by correlation coefﬁcient (r) of 0.999. The robustness of the method was evaluated by delib-
erately altering the chromatographic conditions. The developed method can be applicable for
routine quantitative analysis.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Non-steroidal anti-Inﬂammatory drugs (NSAIDs) are used for
the management of pain and inﬂammation associated with
musculo-skeletal, joint disorders and operative procedures.The uses of these drugs are prevalent in India due to the high
rates of occurrence of rheumatoid disorders. Many NSAIDs
have been marketed, one among them is Ketorolac Trometha-
mine. It is chemically, (±)-5-benzoyl-2,3-dihydro-1H-pyrroli-
zine-1-carboxylic acid, 2-amino-2-(hydroxymethyl)-1,3-
propanediol (Fig. 1). In India it is marketed under the trade
name of Acular LS and Acular PS. When administered as
eye drops it demonstrated analgesic, anti-histaminic, anti-
inﬂammatory and anti-pyretic activity. The mechanism of ac-
tion is to inhibit prostaglandin biosynthesis and given system-
ically does not cause pupil constriction.
Several studies for the estimation of the Ketorolac Trometh-
amine drug using various techniques have been carried out,
some of them being; Simultaneous spectrophotometric
Figure 2 UV absorbance spectra.
Figure 1 Chemical structure of Ketorolac Tromethamine.
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dosage forms (Fegade et al., 2009). Formulation and evaluation
of mouth dissolving tablet of Ketorolac Tromethamine for the
management using super disintegrants (Patil et al., 2009).
Formulation and development of enteric coated dosage form
using Ketorolac Tromethamine (Rupesh et al., 2010). Stability
indicating the HPLC method for the simultaneous determina-
tion of Moxiﬂoxacin Hydrochloride and Ketorolac Trometha-
mine in pharmaceutical dosage form (Naeem et al., 2011).
Revalidation and analytical evaluation of Ketorolac Trometha-
mine by HPTLC using reﬂectance scanning densitometry (Rao
et al., 2011). Preparation and evaluation of Ketorolac Trometh-
amine Gel containing genipin for periodontal diseases (Jeon
et al., 2007). Absorption ratio method for the estimation of
Moxiﬂoxacin HCl and Ketorolac Tromethamine in their com-
bined dosage form by UV–Visible spectroscopy (Gandhi et al.,
2011). Simultaneous determination of Ketorolac Trometha-
mine and Furosemide in intestinal perfusion samples by
validated Reversed Phase High Performance Liquid Chroma-
tography (Gupta et al., 2005). Formulation and evaluation of
an ophthalmic delivery system of the Non-steroidal Anti-
Inﬂammatory Drug (NSAID), Ketorolac Tromethamine based
on the concept of pH-triggered in situ gelation (Kugalur et al.,
2010). Voltametric behavior of Ketorolac and its determination
in HPLC-EC (Squella et al., 2006).
2. Experimental procedures
2.1. Instruments
Waters 2695 with 22996 PDA detector HPLC systems (Em-
power 2 software), Sartorius Electronic Analytical balance,
Crest sonicator and Kromosil C18 column (150 cm ·
4.6 mm · 5 l) were used.
2.2. Chemicals and reagents
Free gift sample of Ketorolac Tromethamine was obtained
from Spectra Pharma Research Laboratories, Hyderabad. A
pharmaceutical product (ACULAR LS and ACULAR PS
eye drops) composition containing the same amount of drug
formulations was used in the experiments. HPLC grade meth-
anol and ammonium dihydrogen phosphate were procured
from Merck Laboratories, Mumbai. HPLC grade deionized
water was used throughout the experiment.
2.3. Buffer preparation
Ammonium dihydrogen phosphate (5.75 g) was dissolved in
1000 mL of distilled water and adjusted the pH to 3.0 with
O-phosphoric acid. It was ﬁltered through 0.45 lm nylon
membrane ﬁlter and degassed. It was used as diluents for the
preparation of sample and standard.3. Method
3.1. Wavelength detection
Accurately weighed Ketorolac Tromethamine equivalent to
100 mg in 100 ml volumetric ﬂask, 100 ml of methanol were
added, sonicated for 5 min and ﬁltered through 0.45 lm nylon
membrane ﬁlter. Pipette out 1 mL of the above solution and
dilute to 10 mL with methanol in 10 mL volumetric ﬂask and
scanned between 200 and 400 nm by UV spectroscopy (Fig. 2).
3.2. Chromatographic conditions
Chromatographic separation was achieved at 30 C, the detec-
tion was carried at 314 nm at a ﬂow rate of 1.5 mL min1 and
run time was kept at 20 min. Prior to the injection of drug
solution column was equilibrated for 60 min with the mobile
phase ﬂowing through the system. The injection volume was
10 lL for assay level. Blank containing the mobile was injected
to check the solvent interference.
3.3. Standard preparation
Ketorolac Tromethamine (100 mg) was weighed and trans-
ferred into a 100 mL volumetric ﬂask and make up to the vol-
ume with diluent. Pipette out 1 mL of the above solution is
diluted 10 mL with the mobile phase to get the ﬁnal concentra-
tion of 100 lg mL1. A representative chromatogram of the
standard was shown in Fig. 3.
3.4. Sample preparation
ACULAR LS and ACULAR PS ophthalmic sample solution
equivalent to 20 mg of Ketorolac Tromethamine was weighed
and transferred to 100 mL volumetric ﬂask. To the above solu-
tion was added 70 mL of the mobile phase, sonicated for about
15 min and ﬁltered through 0.45 lm nylon membrane ﬁlter.
1.25 mL of the ﬁltrate was diluted to 10 mL with the mobile
phase. A representative chromatogram of the sample was
shown in Fig. 4 and Table 1.
Figure 3 Standard chromatogram.
Figure 4 Test chromatogram.
Table 1 Analysis of marketed formulations.
Commercial formulation Ingredients Labeled amount
(mg)
Amount found
(mg) n= 6
Found
in (%)
Acular LS eye drops Ketorolac Tromethamine 0.4 0.43 102
Acular PF eye drops Ketorolac Tromethamine 0.4 0.42 101
S930 G. Sunil et al.3.5. Evaluation of system suitability
10 lL of standard solution was injected in six duplicate be-
fore and after the analysis and the chromatograms were re-
corded. System suitability parameters like column efﬁciency,
plate count and tailing factor were also recorded. The column
efﬁciency determined was found to be more than 2000 USP
plate count, USP Tailing for the same peak is not more than
2.0 and % RSD of six injection of the standard solution is
not more than 2.0% the chromatogram as shown in Fig. 5
and Table 2.4. Analytical method validation (ICH, 2005)
4.1. Speciﬁcity
Placebo solution was prepared as per the test solution using
equivalent weight of the placebo in a portion. Placebo solution
was injected into the HPLC system following the test condi-
tions, the chromatogram was recorded and measured the
responses of the peaks were noted for any interference of the
excipient at the retention time of Ketorolac Tromethamine
(Fig. 6).
Figure 5 System suitability chromatogram.
Figure 6 Placebo (Speciﬁcity) chromatogram.
Table 2 System suitability study.
Injection RT Peak area USP plate count USP tailing factor
1 6.085 2606836 2011 1.28
2 6.049 2698061 2008 1.27
3 6.034 2530365 2176 1.22
4 6.021 2591486 2218 1.21
5 5.983 2572701 2136 1.25
Mean 6.0344 2596031.33 2108 1.24
SD 0.037401 61905.95 – –
% RSD 0.006 0.0238 – –
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Precision was measured in terms of repeatability of application
and measurement. Repeatability of standard application
(system precision) was carried out using six replicates of the
sample injection (100 lg mL1). Repeatability of sample mea-
surement (method precision) was carried out in six different
sample preparations from the same homogenous blend of the
marketed sample (100 lg mL1). The percentage RSD for
repeatability of standard preparation was 1.16% whereas the% RSD for repeatability of the sample preparation was
0.02%. This shows that the precision of the method is satisfac-
tory as percentage RSD is not more than 2% the chromato-
gram as shown in Figs. 7 and 8 and Table 3.
4.3. Linearity
The linearity of Ketorolac Tromethamine was determined by
preparing and injecting a solution with a concentration of about
50–150 lg mL1. The calibration curve indicates the response is
Figure 7 Precision chromatogram.
Figure 8 Intermediate precision chromatogram.
Table 3 Precision study of the method.
S. no Sample area % Assay Amount present (mg)
1 2606386 100.4 0.47
2 2698061 103.9 0.48
3 2530365 97.47 0.43
4 2591486 99.82 0.46
5 257270 99.19 0.45
6 2576739 99.25 0.46
MEAN 99.99 0.45
SD 56171.2
% RSD 1.16
S932 G. Sunil et al.linear over the concentration range studied for Ketorolac Tro-
methamine with a correlation coefﬁcient (r) of 0.999.
4.4. Stability of sample solution
The sample solution was prepared as per the test method, and
analyzed initially at different time intervals by keeping the
solution at room temperature. The percentage responsebetween the initial and different time intervals shows that the
sample solutions were stable for at least 24 h at room temper-
ature (Table 4).
4.5. Robustness
Robustness of the method was determined by analyzing the
standard solution at normal operating conditions by changing
Table 4 Stability study.
S. no Time interval (h) Peak response
1 0 2606836
2 2 2698061
3 6 2530365
4 10 2591486
5 16 2572701
6 24 2576739
Mean 2596031.33
SD 51277.56
% RSD 0.019
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umn, oven temperature, detection wavelength and the mobile
phase. The conditions with variation and their results were
shown in Table 5. The tailing factor is around unity indicative
of peak symmetry and theoretical plate counts were also above
2000. Hence robustness of the extent of variations applied to
analytical conditions was shown in Fig. 9.
4.6. Accuracy
The percentage recovery experiments were performed by add-
ing a known quantity of pure standard drug into the pre-ana-
lyzed sample. The solution equivalent to 100 mg of Ketorolac
Tromethamine was accurately weighed into a 100 mL volumet-
ric ﬂask. The sample was then spiked with standard at levelFigure 9 Robustnes
Table 5 Robustness studies.
System suitability parameters
(variations)
% RSD of peak
response (n= 3
Change in (%) +5 1.20
Organic phase 5 1.23
Change in pH +3 0.019
3 0.017
Change in ﬂow +1.5 0.004
1.5 0.003
Change in temp. +25 0.00350%, 100% and 150% of test concentration. The resulting
spiked sample solutions were assayed in triplicate and the re-
sults were compared and expressed as percentage. The mean
percentage recovery of Ketorolac Tromethamine was found
to be in the range between 98.54 and 102.5 which are within
the acceptance limits as shown in Table 6 and Fig. 10.
4.7. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The limit of detection (LOD) is the lowest amount of analyte
in a sample that can be detected, but not necessarily quantiﬁed,
under the stated experimental conditions. LOD and LOQ were
calculated by using standard deviation and slope values ob-
tained from the calibration curve by using the formula
LOD= 3.3 (SD/S) and LOQ= 10 (SD/S). The LOD and
LOQ values for Ketorolac Tromethamine were found to be
0.116 lg mL1 and 0.32 lg mL1 respectively as shown in
Figs. 11 and 12 and Table 7.
5. Results and discussion
A different combination of mobile phases and chromato-
graphic conditions were tried and a mobile phase containing
ammonium dihydrogen phosphate and methanol (44:55 V/V),
Kromosil C18 (150 cm · 4.6 mm · 5 l) column, 1.5 mL min1
ﬂow rate, 10 lL injection volume, 30 C column oven tempera-
ture, 314 nm wavelength and 20 min run time was found to bes chromatogram.
area
)
Mean tailing
factor (n= 3)
Mean retention time
in min (n= 3)
0.67 6.01
0.86 6.05
1.28 6.06
1.30 6.08
1.22 6.75
1.25 6.85
1.19 5.18
Figure 10 Accuracy chromatogram.
Figure 11 LOD.
Table 6 Accuracy study.
Spike level (%) Amount added in (lg mL1) Peak area % Recovery % Mean recovery
50 0.12 1347374 103.90 102.5
50 1308694 100.83
50 1336027 102.93
100 0.25 2635598 101.54 99.44
100 2575802 99.32
100 2530358 97.48
150 0.36 3532611 96.23 98.54
150 3858796 99.10
150 3906218 100.31
S934 G. Sunil et al.suitable for all combinations. These chromatographic condi-
tions gave retention time of 6.01 min. Speciﬁcity of the method
was checked by injecting the placebo solution, no peaks were
found at the retention time of Ketorolac Tromethamine. The
stability of the sample solution was evaluated by preparing a
sample solution as per the proposed method and analyzed ini-tially and at 1 h intervals up to 24 h by keeping the sample solu-
tion at room temperature. The results of the stability studies
showed that the solution of the drug was found to be stable
for 24 h at room temperature. System precision and method
precision results showed the % RSD of 1.16 and 0.02, respec-
tively. A good linearity relationship indicated by correlation
Figure 12 LOQ.
Table 7 LOD and LOQ.
S. no Concentration
(lg mL1)
Peak area
1 50 1341056
2 70 1814323
3 100 2582490
4 120 3087955
5 150 3877114
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tions of 50–150 lg mL1 of Ketorolac Tromethamine. Interme-
diate Precision was done by changing the analyst, column, with
the same chromatographic conditions and the obtained results
were within the limits. The Robustness method was evaluated
by deliberately varying the chromatographic conditions of the
method such as mobile phase methanol content, ﬂow rate, col-
umn temperature and wavelength. The parameters like tailing
factor and retention time showed adherence to the limits. The
accuracy of the method was determined and the percentage
recovery was calculated. The data indicate an average of
102.5% recovery of the standard sample.6. Conclusion
The method developed for Ketorolac Tromethamine was
found to be a simple process and the procedure does not in-
volve any experimental conditions. The validation results indi-
cated that the method was speciﬁc, accurate, linear, precise,
rugged and robust. The runtime was relatively 20 min which
enabled a rapid quantiﬁcation of many samples in routine
and quality control analysis of ophthalmic formulation.Acknowledgement
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